Hung et al developed a score for evaluating a patient with hepatitis B virus-associated hepatocellular carcinoma (HCC) following resection of the tumor. This can help to identify a patient at risk for recurrence. The authors are from the University of Hong Kong, Queen Mary Hospital, and the Hospital Authority of Hong Kong.
Patient selection: HBV-related hepatocellular carcinoma following surgical resection
Outcome: recurrent hepatocellular carcinoma (HCC)
Parameters:
(1) lymphovascular invasion
(2) microsatellite lesions
(3) serum alpha-fetoprotein in ng/mL
(4) HBV anti-viral therapy prior to resection
(5) post-resection HBV copies in IU/mL at one month following tumor resection (viral load)
Parameter |
Finding |
Points |
lymphovascular invasion |
no |
0 |
|
yes |
1.01 |
microsatellite lesion(s) |
no |
0 |
|
yes |
1.03 |
serum AFP |
<= 100 ng/mL |
0 |
|
> 100 ng/mL |
0.43 |
HBV antiviral therapy |
no |
0 |
|
yes |
-2.9 |
HBV viral load at 1 month following resection |
<= 20,000 IU/mL |
0 |
|
> 20,000 IU/mL |
0.45 |
where:
• In the text the scoring says < 100 but context elsewhere is > 100.
PRIP score =
= SUM(points for all 5 parameters) - 0.45
Interpretation:
• minimum score: -3.35
• maximum value: 2.47
• The higher the score the greater the risk of recurrent hepatocellular carcinoma.
Score |
Recurrence |
-3.35 to 0 |
(3.46 * ((points)^2)) + (22 * (points)) + 35.15 |
0 to 2.47 |
(-6.777*((points)^2)) + (43.49 * (points)) + 34.38 |
Performance:
• The AUC was 0.68 for 1 year recurrence.
• The AUC was 0.75 for 3-year recurrence.
Specialty: Hematology Oncology, Surgery, general, Gastroenterology